Contact us Demo our platform

Case Study

Evaluating the Effect of a Novel Alzheimer’s Disease (AD) Drug

CAD-31 leads to a shift in lipid metabolism, including increases in acylcarnitines, acetyl-CoA, and ketone bodies.

The Metabolon Global Discovery Panel was utilized to establish a CAD-31 metabolomic signature that includes novel biomarkers for treating Alzheimer’s disease. The data from this study demonstrate that in a mouse model of AD, CAD-31 has therapeutic efficacy on the cognitive and physiological parameters of AD. The changes identified in the metabolite profile of CAD-31-treated mice are necessary to determine the physiological consequences of CAD-31 exposure and find markers for target engagement.

Talk With An Expert About Your Project

The Metabolon Global Discovery Panel was utilized to establish a CAD-31 metabolomic signature that includes novel biomarkers for treating Alzheimer’s Disease. The data from this study demonstrate that in a mouse model of AD, CAD-31 has therapeutic efficacy on the cognitive and physiological parameters of AD. The changes identified in the metabolite profile of CAD-31-treated mice are necessary to determine the physiological consequences of CAD-31 exposure and find markers for target engagement.

Talk With An Expert About Your Project
Evaluating the Effect of a Novel Alzheimer's Disease (AD) Drug

The Challenge: Understanding the Effect of a Novel Alzheimer’s Disease (AD) Drug

Alzheimer’s disease (AD) is a progressive neurological disorder that causes the brain to atrophy and brain cells to die. AD is the most common cause of dementia, affecting memory, thinking, and behavior. Symptoms of AD eventually become severe enough to interfere with daily tasks. In its early stages, memory loss is mild, but with late-stage AD, individuals lose the capacity to converse, respond to their environment, and function independently. A worldwide effort is underway to find better ways to treat AD, delay its onset, and prevent it from developing. Current therapies may temporarily improve or slow the progression of symptoms; however, no treatment prevents the death of nerve cells in AD. A research group recently synthesized a drug called CAD-31 that was shown to enhance neurogenetic activity in vitro.1 However, to move CAD-31 toward the clinic, further characterization was necessary to demonstrate further the neurogenic, neuroprotective, and memory-enhancing effects of this drug.

Metabolon Insight: Elucidating Potential Biomarkers for CAD-31 Therapy

This study utilized the Metabolon Global Discovery Panel to profile brain (cortex) and plasma samples from drug-treated and vehicle-treated AD and wild-type (WT) mice.1 The goal was to elucidate potential biomarkers for CAD-31 therapy and to further understand the effect that CAD-31 has on metabolism. The Metabolon Global Discovery Panel‘s unrivaled reference dataset of 5,400+ semi-quantifiable analytes offered this group the most comprehensive solution to reveal novel biomarkers of CAD-31 treatment.

The Solution: CAD-31 Leads to a Shift in Lipid Metabolism

The research team studied the effect of CAD-31 in a mouse model of AD at a stage when AD was significantly advanced and examined if CAD-31 could rescue AD-associated deficits. This study demonstrated that when CAD-31 was fed to AD mice for three months, there was a reduction in memory deficit, brain inflammation, and synaptic loss.

Metabolomics data from the brain and plasma of CAD-31-treated and vehicle-treated mice showed that the most prominent effect of CAD-31 is centered on lipid metabolism. The top pathways modified in the plasma of WT mice by CAD-31 were long-chain fatty acids, ketone bodies, acyl carnitines, and sphingolipids. In contrast to the effect of CAD-31 on WT mice, the only significant pathway altered in the plasma of the CAD-31-treated AD group compared with control AD mice was the sphingolipids pathway. The results for brain metabolites of WT mice followed a similar pattern since most changes also occurred in lipid metabolism. In WT mice, long-chain fatty acids and monoacylglycerols were downregulated by CAD-31, whereas acetyl-CoA, acyl carnitines, and ketone bodies were upregulated by CAD-31. The only significant drug effect in AD mice was an increase in monoacylglycerols. Altogether, these metabolic data suggest that CAD-31 leads to a shift in lipid metabolism, reflected by increases in acylcarnitines, acetyl-CoA, and ketone bodies.

The Outcome: Establishing a Metabolomic Signature for CAD-31

The Metabolon Global Discovery Panel was utilized to establish a CAD-31 metabolomic signature that includes novel biomarkers for treating CAD-31. The data from this study demonstrates that in a mouse model of AD, CAD-31 has therapeutic efficacy on the cognitive and physiological parameters of AD. CAD-31 reversed the cognitive deficiencies in AD mice to levels seen in age-matched control animals. The changes identified in the metabolite profile of CAD-31-treated mice are necessary to determine the physiological consequences of CAD-31 exposure and find markers for target engagement.

References

1. Daugherty D, Goldberg J, Fischer W, Dargusch R, Maher P, Schubert D. A novel Alzheimer’s disease drug candidate targeting inflammation and fatty acid metabolism. Alzheimers Res Ther. 2017 Jul 14;9(1):50. doi: 10.1186/s13195-017-0277-3. PMID: 28709449; PMCID: PMC5513091.

Related Case Studies

See All Case Studies
✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.